In relation to our knowledge of phosphatases of LRRK2, α-syn, and tau and the pathogenic nature of phosphorylations in these proteins, a strategy to target phosphatases in a way that will counteract PD-associated phosphorylation can be proposed. The gene discussed is MAPT; the disease is Parkinson disease.